Bionano Genomics, Inc. (Nasdaq: BNGO) today announced that Al Luderer, Ph.D., chairman of Bionano’s Board of Directors, has been appointed interim president and chief executive officer, effective May ...

Biotech company 10x Genomics (NASDAQ:TXG) reported in Q1 CY2026, but sales fell by 2.6% year on year to $150.8 million. The ...

Prospective parents can now pick embryos based on risk predictions for thousands of diseases and odds for specific traits.

What Happened? Shares of biotech company 10x Genomics (NASDAQ:TXG) fell 5.3% in the afternoon session after its first-quarter ...

Every cell in the body holds a story written in three billion letters. For decades, scientists struggled to translate that code into something they understood and could use. On a sunny Santa Cruz ...

A more predictive, preventive approach to medicine can enable more accurate population-level risk assessments and predictions ...

Fiscal 2026 Outlook and Atara Launch Dynamics Full-year 2026 revenue guidance of $600 million to $625 million assumes ...

A member of the UCSC Braingeneers group talks with symposium attendees about their research with brain organoids. Photo Credit: Anusha Ravishankar. Twenty-five years ago, UC Santa Cruz played a ...

The research, published on April 24th, 2026, in Nature Microbiology, describes how the new tool, called TRAnsmision ...

PLEASANTON, Calif., May 7, 2026 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, today reported financial results for ...

TXG) on Thursday reported a loss of $13.5 million in its first quarter. The Pleasanton, California-based company said it had a loss of 10 cents per share. The results beat Wall Street expectations.

Increasing prevalence of bleeding disorders, rising number of surgical procedures, aging population, and growing focus on interoperability are the major factors which drive global market growth.WILMIN ...